Fluorescent Risedronate Analogues and Their Effects on Bone Cells
Author Information
Author(s): Anke J Roelofs, Fraser P Coxon, Frank H Ebetino, Mark W Lundy, Zachary J Henneman, George H Nancollas, Shuting Sun, Katarzyna M Blazewska, Joy Lynn F Bala, Boris A Kashemirov, Aysha B Khalid, Charles E McKenna, Michael J Rogers
Primary Institution: Institute of Medical Sciences, University of Aberdeen
Hypothesis
Do bisphosphonates affect non-osteoclast cells in vivo?
Conclusion
The study shows that bisphosphonates may have direct effects on bone marrow monocytes in addition to their known effects on osteoclasts.
Supporting Evidence
- Fluorescent risedronate analogues were bound to bone surfaces within 24 hours after injection.
- High levels of uptake of fluorescently labeled risedronate were observed in CD14high bone marrow monocytes.
- Fluorescent risedronate analogues localized around osteocytes and vascular channels in bone.
Takeaway
This study found that certain drugs used for bone health can also affect other types of cells in the bone, not just the ones that break down bone.
Methodology
Fluorescent risedronate analogues were injected into mice and rabbits to study their uptake and localization in bone and bone marrow cells.
Limitations
The study primarily used animal models, which may not fully represent human responses.
Participant Demographics
3-month-old mice and newborn rabbits were used in the study.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website